A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.
An article from
Dive Brief
A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.
Published June 8, 2026
A stained image of pancreatic ductal adenocarcinoma, the cancer that Tango Therapeutics' vopimetostat is intended to treat.
Why Is Tango Therapeutics Stock Soaring Monday? - Tango Therapeutics (NASDAQ:TNGX)
Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
Tango plans Phase 3 pancreatic cancer study after combo success
Vopimetostat-daraxonrasib combo ‘extremely encouraging’ in metastatic pancreatic cancer
Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday - Ame
Does Revolution Medicines' pancreatic cancer drug have even greater potential?
For pancreatic cancer patients, an exciting drug can feel out of reach
Tumore al pancreas, perché il farmaco di Revolution Medicines è rivoluzionario - Startmag
What RevMed's pancreatic cancer drug meant for one patient
Tango Therapeutics reports 90% 6-month PFS in pancreatic cancer trial. Read about the vopimetostat combo driving TNGX stock up.
A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an…
Tango Therapeutics reports 92% ORR from vopimetostat plus daraxonrasib combo in pancreatic cancer, plans Phase 3 study later this…
A two-drug combination exhibited durable clinical benefit as second- or third-line treatment for pancreatic cancer, according to…
U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive trial data. Other big gainers…
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically…
